查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1755979

Herceptin生物相似藥市場預測至 2032 年：按類型、劑量、分銷管道、應用、最終用戶和地區進行的全球分析

Herceptin Biosimilar Market Forecasts to 2032 - Global Analysis By Type (Ogivri, Herzuma, Ontruzant, Trazimera and Other Types), Dosage, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2025 年全球Herceptin生物相似藥市場價值為 48.9 億美元，預計到 2032 年將達到 106.6 億美元，預測期內複合年成長率為 11.77%。

與FDA核准的參考產品曲妥珠單抗（Herceptin）非常相似的生物製藥稱為Herceptin生物相似藥。該藥物由活細胞開發，透過靶向某些胃癌和乳癌中的HER2蛋白來抑制細胞生長。生技藥品結構複雜，無法完全複製，但經過全面的測試，可以確保其在效力、安全性和純度方面不存在臨床顯著差異。生物相似藥具有相似的療效和副作用，而且通常價格更低，從而增加了患者獲得基本癌症治療的機會。

Herceptin專利到期

Herceptin的專利到期為其他製藥公司生產和銷售完全相同的藥物鋪平了道路。生物相似藥的湧現瞬間為市場帶來了巨大的競爭，這對市場的成長至關重要。反過來，競爭的加劇降低了基於曲妥珠單抗的療法的成本。更低的成本使這些拯救生命的療法更容易被全球更多患者獲得，並負擔得起。最終，將壟斷市場轉變為競爭環境的主要驅動力是專利到期。

製造複雜性和監管挑戰

生物相似藥需要先進的生物技術工藝，因此難以複製並保持穩定的品質。嚴格的監管規定要求進行大規模臨床試驗以驗證生物相似藥的有效性，這進一步加劇了市場准入的複雜性。由於不同地區的核准途徑不同，全球商業化也面臨更多障礙。這些障礙阻礙了新進入者，限制了競爭，並減緩了市場成長。最終，患者可能無法獲得更便宜的替代藥物。

全球乳癌和胃癌發生率上升

隨著越來越多患者的確診，對曲妥珠單抗等高效能 HER2標靶治療的需求必然會增加。Herceptin生物相似藥將為昂貴的原廠藥提供更經濟、更重要的替代方案。這種成本效益將改善病患獲得緊急醫療的管道，尤其是在醫療資金緊張的農村地區。因此，隨著疾病負擔的增加直接影響處方量和藥物的採用，Herceptin生物相似藥市場預計將大幅成長。

強大的品牌忠誠度和醫療保健提供者的抵制

許多專業人士和消費者偏好知名品牌，因為他們信賴產品和服務的可靠性。這種品牌忠誠度會阻礙人們嘗試更新或不同的出行方式。此外，醫療專業人士通常不願意推薦不知名的品牌，因為他們擔心潛在的責任或病人不滿意。這種抵制限制了新業務和原創設計進入市場，扼殺了競爭，並減緩了市場發展。

COVID-19的影響

新冠疫情對Herceptin生物相似藥市場產生了多方面的影響。最初，它造成了供應鏈中斷、生產延遲和臨床試驗延遲（尤其是在2020年初）。就診人數的減少和醫療保健重點的轉變也導致癌症治療減少。然而，疫情同時也凸顯了對經濟高效的醫療保健解決方案的迫切需求。這促使包括Herceptin在內的生物相似藥被接受和採用，因為醫療保健系統正在努力控制財務負擔並改善基本藥物的可及性，最終將在長期內加速市場滲透。

Hersma（曲妥珠單抗-PKRB）細分市場預計將成為預測期內最大的細分市場

由於競爭加劇和成本削減的驅動，Herzuma（曲妥珠單抗-PKRB）細分市場預計將在預測期內佔據最大市場佔有率。作為FDA核准的生物相似藥，該藥物提供了一種療效和安全性均與參考產品相當的替代方案。生物相似藥的廣泛使用，尤其是在日本等市場佔有較大佔有率的生物相似藥，增加了患者獲得重要HER2標靶治療方法的可及性。這種競爭壓力將鼓勵生物相似藥的更廣泛應用，有助於降低整體醫療成本。最終，Herzuma的加入將促進全球曲妥珠單抗生物相似藥市場更具活力、更容易取得。

預測期內大腸直腸癌領域預計將錄得最高複合年成長率

由於大量患者可使用曲妥珠單抗治療，預計大腸直腸癌領域將在預測期內達到最高成長率。Herceptin生物相似藥是比原廠藥更經濟的替代方案，使HER2陽性大腸直腸癌患者更容易獲得標靶治療。這種可近性的提高，加上結直腸癌發病率的上升以及人們對HER2陽性在該適應症中作用的認知不斷提高，正在推動對生物類似藥的需求。此外，探索曲妥珠單抗對包括大腸直腸癌在內的其他HER2陽性惡性腫瘤療效的研究和臨床試驗，也正在促進市場擴張。最終，Herceptin生物相似藥在結直腸癌治療中的成本效益和廣泛應用，推動了市場的顯著成長。

比最大的地區

由於 HER2 陽性癌症發生率上升以及醫療保健可近性的不斷擴大，預計亞太地區將在預測期內佔據最大的市場佔有率。印度和中國等國的本地製造能力以及簡化的監管途徑，正在加速產品上市和市場滲透的速度。由於有利的法規和較低的製造成本，具有成本效益的生物相似藥製劑正越來越容易被中等收入者所接受。醫療保健專業人員和患者意識的不斷提高，加上該地區龐大的人口規模，使得亞太地區在未來幾年內將成為Herceptin生物相似藥最具活力、成長最快的市場。

複合年成長率最高的地區：

在預測期內，北美預計將呈現最高的複合年成長率。這得益於乳癌的高發生率、強大的醫療基礎設施以及完善的生物相似藥核准法律規範。在強大的支付方獎勵和醫生熟悉度的支持下，生物相似藥的早期採用正在推動市場成長。大型製藥公司正在積極進行生物相似藥研究，美國FDA簡化的核准流程進一步支持了商業化。該地區受益於全面的保險覆蓋和成熟的報銷制度，確保了廣泛的患者可及性。然而，市場面臨著日益激烈的價格競爭、來自替代HER2藥物的競爭以及持續的處方談判。

免費客製化服務：

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球Herceptin生物相似藥市場類型

  • Ogivri（曲妥珠單抗-DKST）
  • Herzuma（曲妥珠單抗-PKR）
  • Ontruzant（曲妥珠單抗-dttb）
  • Trazimera（曲妥珠單抗-qyyp）
  • 坎金蒂人（曲斯圖祖馬佈人）
  • HERCESSI（曲妥珠單抗-STRF）
  • 其他類型

6. 全球Herceptin生物相似藥市場（按劑量）

  • 150毫克/單劑量管瓶
  • 420毫克/多劑量管瓶

7. 全球Herceptin生物相似藥市場（依通路）

  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 直接競標
  • 其他分銷管道

8. 全球Herceptin生物相似藥市場（按應用）

  • 乳癌
  • 胃癌
  • 大腸直腸癌
  • 白血病
  • 淋巴瘤
  • 其他用途

9. 全球Herceptin生物相似藥市場（依最終用戶）

  • 腫瘤中心
  • 專科診所
  • 其他最終用戶

10. 全球Herceptin生物相似藥市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Amgen Inc.
  • Celltrion Healthcare Co., Ltd.
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Biocon Biologics Limited
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Shanghai Henlius Biotech, Inc.
  • Merck & Co., Inc.
  • Stada Arzneimittel AG
  • Accord Healthcare Ltd.
  • BIOCAD
  • AryoGen Pharmed Co., Ltd.
  • Prestige BioPharma Limited
  • EirGenix Inc.
  • Apotex Inc.
  • Gedeon Richter Plc.
Product Code: SMRC29873

According to Stratistics MRC, the Global Herceptin Biosimilar Market is accounted for $4.89 billion in 2025 and is expected to reach $10.66 billion by 2032 growing at a CAGR of 11.77% during the forecast period. A biological medication that closely resembles trastuzumab (Herceptin), the original FDA-approved reference product, is known as a Herceptin biosimilar. Constructed from living cells, it blocks cell development by targeting the HER2 protein in some gastric and breast malignancies. Because biologics are complicated, they cannot be exactly replicated, but thorough testing guarantees that there are no clinically significant variations in potency, safety, or purity. Biosimilars increase patient access to essential cancer treatments by providing similar efficacy and side effect profiles, frequently at a cheaper cost.

Market Dynamics:

Driver:

Patent expiry of herceptin

It cleared the path for other pharmaceutical companies to create and market very identical versions once the patent protection expired. Significant market rivalry was instantly brought about by this flood of biosimilars, which is essential for market growth. Consequently, increased competition lowers the cost of treatments based on trastuzumab. Reduced costs make these life-saving procedures more accessible and affordable for a larger number of patients worldwide. In the end, the primary facilitator that turns a monopolised market into a competitive environment is patent expiration.

Restraint:

High manufacturing complexity and regulatory challenges

Biosimilars require advanced biotechnological processes, making them difficult to replicate with consistent quality. Regulatory challenges further complicate market entry, as stringent guidelines demand extensive clinical trials to prove biosimilarity. Approval pathways vary across regions, adding additional hurdles for global commercialization. These barriers discourage new entrants and limit competition, slowing market growth. As a result, patients may experience reduced access to affordable alternatives.

Opportunity:

Rising incidence of breast and gastric cancers globally

The need for efficient HER2-targeted treatments, like as trastuzumab, inevitably rises as more people receive diagnoses. Biosimilars of Herceptin provide a vital, less expensive substitute for the pricey original medication. This cost-effectiveness increases patient access to life-saving care, especially in underdeveloped areas where healthcare finances are tight. Since a result, the market for Herceptin biosimilars is expected to develop significantly since the rising illness burden directly affects prescription volume and adoption.

Threat:

Strong brand loyalty and resistance from healthcare providers

Many experts and consumers favour well-known brands because they have faith in the dependability of the products and services. This devotion makes people less inclined to try out newer or different mobility alternatives. Furthermore, medical professionals frequently hesitate to suggest unknown brands out of concern for potential liability or patient unhappiness. Such opposition restricts new businesses' and creative designs' ability to enter the market. As a result, this hinders competition and delays the general development of the market.

Covid-19 Impact

The COVID-19 pandemic presented a mixed impact on the Herceptin biosimilar market. Initially, it caused supply chain disruptions, manufacturing slowdowns, and delays in clinical trials, particularly in early 2020. Reduced hospital visits and shifted healthcare priorities also led to a decline in oncology treatments. However, the pandemic concurrently highlighted the urgent need for cost-effective healthcare solutions. This spurred greater acceptance and adoption of biosimilars, including Herceptin biosimilars, as healthcare systems sought to manage financial burdens and increase access to essential medicines, ultimately accelerating their market penetration in the long term.

The herzuma (trastuzumab-pkrb) segment is expected to be the largest during the forecast period

The herzuma (trastuzumab-pkrb) segment is expected to account for the largest market share during the forecast period, due to intensified competition and driving down costs. As an FDA-approved biosimilar, it offers a proven, equally efficacious, and safe alternative to the reference product. Its widespread availability, particularly in markets like Japan where it has captured substantial share, increases patient access to vital HER2-targeted therapy. This competitive pressure encourages broader adoption of biosimilars, contributing to overall healthcare cost savings. Ultimately, Herzuma's presence fosters a more dynamic and accessible market for trastuzumab biosimilars globally.

The colorectal cancer segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the colorectal cancer segment is predicted to witness the highest growth rate, due to the treatable patient population for trastuzumab. As Herceptin biosimilars offer a more affordable alternative to the originator drug, their use in HER2-positive colorectal cancer makes targeted therapy more accessible. This increased accessibility, coupled with rising colorectal cancer incidence and growing awareness of HER2 status in this indication, drives demand for biosimilars. Furthermore, research and clinical trials exploring trastuzumab's efficacy in other HER2-positive malignancies, including colorectal cancer, contribute to market expansion. Ultimately, the cost-effectiveness and broadened applicability of Herceptin biosimilars in colorectal cancer treatment foster significant market growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to rising incidence of HER2-positive cancers and expanding healthcare access. Local manufacturing capabilities in countries like India and China, along with streamlined regulatory pathways, have enabled faster product launches and greater market penetration. Cost-effective biosimilar alternatives are increasingly accessible to middle-income populations, supported by favorable regulations and reduced production costs. Growing awareness among healthcare professionals and patients, combined with the region's large population base, positions Asia Pacific as the most dynamic and rapidly expanding market for Herceptin biosimilars in the coming years.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to a high prevalence of breast cancer, robust healthcare infrastructure, and well-established regulatory frameworks for biosimilar approvals. The early adoption of biosimilars, supported by strong payer incentives and physician familiarity, has accelerated market growth. Major pharmaceutical companies actively conduct biosimilar research, and the U.S. FDA's streamlined approval process further supports commercialization. The region benefits from comprehensive insurance coverage and mature reimbursement systems, ensuring broad patient access. However, the market faces increasing pricing pressures, competition from alternative HER2 therapies, and ongoing formulary negotiations.

Key players in the market

Some of the key players profiled in the Herceptin Biosimilar Market include Amgen Inc., Celltrion Healthcare Co., Ltd., Pfizer Inc., Samsung Bioepis Co., Ltd., Biocon Biologics Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Shanghai Henlius Biotech, Inc., Merck & Co., Inc., Stada Arzneimittel AG, Accord Healthcare Ltd., BIOCAD, AryoGen Pharmed Co., Ltd., Prestige BioPharma Limited, EirGenix Inc., Apotex Inc. and Gedeon Richter Plc.

Key Developments:

In November 2024, Celltrion acquired Swiss-based iQone Healthcare for approximately 30 billion KRW. This strategic move aims to enhance Celltrion's European distribution and commercialization capabilities, particularly for biosimilars like Herzuma, by leveraging iQone's established regional market presence.

In December 2023, Pfizer and Roche (via Genentech) reached a confidential settlement resolving U.S. patent litigation over trastuzumab. This agreement cleared a key legal hurdle, enabling Pfizer to proceed with the future launch of its Herceptin biosimilar.

In June 2023, Celltrion expanded its partnership with Rani Therapeutics to supply CT-P17, its adalimumab biosimilar, for development in Rani's oral biologics platform. This collaboration reflects Celltrion's commitment to innovative drug delivery and global pipeline growth, aiming to transform injectable treatments into convenient oral alternatives.

Types Covered:

  • Ogivri (trastuzumab-dkst)
  • Herzuma (trastuzumab-pkrb)
  • Ontruzant (trastuzumab-dttb)
  • Trazimera (trastuzumab-qyyp)
  • Kanjinti (trastuzumab-anns)
  • HERCESSI (trastuzumab-strf)
  • Other Types

Dosages Covered:

  • 150mg/single-dose vial
  • 420mg/multidose vial

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Direct Tender
  • Other Distribution Channels

Applications Covered:

  • Breast Cancer
  • Gastric Cancer
  • Colorectal Cancer
  • Leukemia
  • Lymphoma
  • Other Applications

End Users Covered:

  • Oncology Centers
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Herceptin Biosimilar Market, By Type

  • 5.1 Introduction
  • 5.2 Ogivri (trastuzumab-dkst)
  • 5.3 Herzuma (trastuzumab-pkrb)
  • 5.4 Ontruzant (trastuzumab-dttb)
  • 5.5 Trazimera (trastuzumab-qyyp)
  • 5.6 Kanjinti (trastuzumab-anns)
  • 5.7 HERCESSI (trastuzumab-strf)
  • 5.8 Other Types

6 Global Herceptin Biosimilar Market, By Dosage

  • 6.1 Introduction
  • 6.2 150mg/single-dose vial
  • 6.3 420mg/multidose vial

7 Global Herceptin Biosimilar Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies
  • 7.5 Direct Tender
  • 7.6 Other Distribution Channels

8 Global Herceptin Biosimilar Market, By Application

  • 8.1 Introduction
  • 8.2 Breast Cancer
  • 8.3 Gastric Cancer
  • 8.4 Colorectal Cancer
  • 8.5 Leukemia
  • 8.6 Lymphoma
  • 8.7 Other Applications

9 Global Herceptin Biosimilar Market, By End User

  • 9.1 Introduction
  • 9.2 Oncology Centers
  • 9.3 Specialty Clinics
  • 9.4 Other End Users

10 Global Herceptin Biosimilar Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Amgen Inc.
  • 12.2 Celltrion Healthcare Co., Ltd.
  • 12.3 Pfizer Inc.
  • 12.4 Samsung Bioepis Co., Ltd.
  • 12.5 Biocon Biologics Limited
  • 12.6 Viatris Inc.
  • 12.7 Teva Pharmaceutical Industries Ltd.
  • 12.8 Shanghai Henlius Biotech, Inc.
  • 12.9 Merck & Co., Inc.
  • 12.10 Stada Arzneimittel AG
  • 12.11 Accord Healthcare Ltd.
  • 12.12 BIOCAD
  • 12.13 AryoGen Pharmed Co., Ltd.
  • 12.14 Prestige BioPharma Limited
  • 12.15 EirGenix Inc.
  • 12.16 Apotex Inc.
  • 12.17 Gedeon Richter Plc.

List of Tables

  • Table 1 Global Herceptin Biosimilar Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Herceptin Biosimilar Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Herceptin Biosimilar Market Outlook, By Ogivri (trastuzumab-dkst) (2024-2032) ($MN)
  • Table 4 Global Herceptin Biosimilar Market Outlook, By Herzuma (trastuzumab-pkrb) (2024-2032) ($MN)
  • Table 5 Global Herceptin Biosimilar Market Outlook, By Ontruzant (trastuzumab-dttb) (2024-2032) ($MN)
  • Table 6 Global Herceptin Biosimilar Market Outlook, By Trazimera (trastuzumab-qyyp) (2024-2032) ($MN)
  • Table 7 Global Herceptin Biosimilar Market Outlook, By Kanjinti (trastuzumab-anns) (2024-2032) ($MN)
  • Table 8 Global Herceptin Biosimilar Market Outlook, By HERCESSI (trastuzumab-strf) (2024-2032) ($MN)
  • Table 9 Global Herceptin Biosimilar Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 10 Global Herceptin Biosimilar Market Outlook, By Dosage (2024-2032) ($MN)
  • Table 11 Global Herceptin Biosimilar Market Outlook, By 150mg/single-dose vial (2024-2032) ($MN)
  • Table 12 Global Herceptin Biosimilar Market Outlook, By 420mg/multidose vial (2024-2032) ($MN)
  • Table 13 Global Herceptin Biosimilar Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 14 Global Herceptin Biosimilar Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 15 Global Herceptin Biosimilar Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 16 Global Herceptin Biosimilar Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 17 Global Herceptin Biosimilar Market Outlook, By Direct Tender (2024-2032) ($MN)
  • Table 18 Global Herceptin Biosimilar Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
  • Table 19 Global Herceptin Biosimilar Market Outlook, By Application (2024-2032) ($MN)
  • Table 20 Global Herceptin Biosimilar Market Outlook, By Breast Cancer (2024-2032) ($MN)
  • Table 21 Global Herceptin Biosimilar Market Outlook, By Gastric Cancer (2024-2032) ($MN)
  • Table 22 Global Herceptin Biosimilar Market Outlook, By Colorectal Cancer (2024-2032) ($MN)
  • Table 23 Global Herceptin Biosimilar Market Outlook, By Leukemia (2024-2032) ($MN)
  • Table 24 Global Herceptin Biosimilar Market Outlook, By Lymphoma (2024-2032) ($MN)
  • Table 25 Global Herceptin Biosimilar Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 26 Global Herceptin Biosimilar Market Outlook, By End User (2024-2032) ($MN)
  • Table 27 Global Herceptin Biosimilar Market Outlook, By Oncology Centers (2024-2032) ($MN)
  • Table 28 Global Herceptin Biosimilar Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 29 Global Herceptin Biosimilar Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.